The role of chemotherapy in cancer treatment: development of a valid and adaptable benchmark rate of optimal chemotherapy utilization

Image - The role of chemotherapy in cancer treatment: development of a valid and adaptable benchmark rate of optimal chemotherapy utilization

The Centre for Big Data Research in Health (CBDRH) is pleased to invite you to a seminar as part of the CBDRH Seminar Series.

We are delighted to host guest speaker Dr Susannah Jacob from the Collaboration for Cancer Outcomes Research and Evaluation (CCORE) who will be presenting on:

"The role of chemotherapy in cancer treatment: development of a valid and adaptable benchmark rate of optimal chemotherapy utilisation."

Summary: There is wide variation in the proportion of newly diagnosed cancer patients who receive chemotherapy, indicating the need for a benchmark rate of chemotherapy utilisation. This study describes an evidence-based model that estimates the proportion of new cancer patients in whom chemotherapy is indicated at least once (defined as the optimal chemotherapy utilisation rate). Models of optimal chemotherapy utilisation were constructed for each cancer site based on indications for chemotherapy identified from evidence-based treatment guidelines. Data on the proportion of patient and tumour-related attributes for which chemotherapy was indicated were obtained, using population-based data where possible. Treatment indications and epidemiological data were merged to calculate the optimal chemotherapy utilisation rate. The optimal chemotherapy utilisation rate can act as a benchmark for measuring and improving the quality of care.

Please see https://susannahjacob.inghaminstitute.org.au/ for further details on Susannah and the Collaboration for Cancer Outcomes Research and Evaluation (CCORE) https://swscs.med.unsw.edu.au/group/collaboration-cancer-outcomes-resear....

Event date
Tuesday, 12 December 2017 - 12:00pm to 1:00pm
File Attachment
Location
Mathews 103
Back to Top